Universal Corporation Reports Nine Month Results
Universal Corporation (NYSE:UVV) reported robust results for the nine months and quarter ending December 31, 2022, driven by a significant increase in tobacco shipments, up 29% to $1.9 billion in consolidated revenue. Operating income rose 25% to $128.7 million, while diluted earnings per share improved by 16% to $2.82. Demand for leaf tobacco remains strong, though the Ingredients Operations segment faced temporary demand softening. Selling, general, and administrative expenses increased due to higher costs and compensation. The company successfully refinanced its bank credit facility, which should support future financial needs.
- Consolidated revenue increased by 29% to $1.9 billion.
- Operating income rose 25% to $128.7 million.
- Diluted earnings per share improved 16% to $2.82.
- Strong tobacco shipment volumes and prices contributed to revenue growth.
- Successful refinancing of bank credit facility supports future financial needs.
- Selling, general, and administrative expenses rose by 18% to $206.8 million.
- Ingredients Operations segment faced temporary demand softening.
- Gross profit margin decreased from 19.7% to 17.9%.
"There continues to be significant demand for leaf tobacco with all types of leaf tobacco currently in an undersupply position. Short burley tobacco crops in
"In our Ingredients Operations segment, we recently have been experiencing some softening of demand for some of our ingredients products which we believe is temporary and largely due to customers adjusting their inventory levels. Some of our ingredients customers have been carrying higher inventory levels because of supply chain uncertainties. Increased costs, particularly selling, general, and administrative expenses, including costs related to the expansion of sales and product development resources and deferred compensation costs from acquisitions, reduced our results for our Ingredients Operations segment in the quarter and nine months ended
"We remain excited about the long-term outlook for our ingredients businesses and continue to make significant capital investments to enhance and increase the capabilities of our plant-based ingredients platform. We are ahead of achieving some of the earlier identified operational synergies across the platform and making considerable progress on our vision for the segment. As announced on
"We successfully refinanced and expanded our bank credit facility in the quarter ended
"Our fiscal year 2022 Sustainability Report was published in
FINANCIAL HIGHLIGHTS | |||||||||||||||||||||||
Nine Months Ended | Change | ||||||||||||||||||||||
(in millions of dollars, except per share data) | 2022 | 2021 | $ | % | |||||||||||||||||||
Consolidated Results | |||||||||||||||||||||||
Sales and other operating revenue | $ | 1,875.8 | $ | 1,456.6 | $ | 419.2 | 29 | % | |||||||||||||||
Cost of goods sold | $ | 1,540.4 | $ | 1,170.0 | $ | 370.4 | 32 | % | |||||||||||||||
Gross Profit Margin | 17.9 | % | 19.7 | % | -180 bps | ||||||||||||||||||
Selling, general and administrative expenses | $ | 206.8 | $ | 175.5 | $ | 31.3 | 18 | % | |||||||||||||||
Restructuring and impairment costs | $ | — | $ | 10.5 | $ | (10.5) | (100) | % | |||||||||||||||
Operating income (as reported) | $ | 128.7 | $ | 103.2 | $ | 25.5 | 25 | % | |||||||||||||||
Adjusted operating income (non-GAAP)* | $ | 128.7 | $ | 116.5 | $ | 12.2 | 10 | % | |||||||||||||||
Diluted earnings per share (as reported) | $ | 2.82 | $ | 2.44 | $ | 0.38 | 16 | % | |||||||||||||||
Adjusted diluted earnings per share (non-GAAP)* | $ | 2.80 | $ | 2.76 | $ | 0.04 | 1 | % | |||||||||||||||
Segment Results | |||||||||||||||||||||||
Tobacco operations sales and other operating revenues | $ | 1,642.7 | $ | 1,268.6 | $ | 374.1 | 29 | % | |||||||||||||||
Tobacco operations operating income | $ | 119.0 | $ | 105.6 | $ | 13.4 | 13 | % | |||||||||||||||
Ingredients operations sales and other operating revenues | $ | 233.2 | $ | 188.0 | $ | 45.1 | 24 | % | |||||||||||||||
Ingredient operations operating income | $ | 9.9 | $ | 10.6 | $ | (0.7) | (7) | % |
*See Reconciliation of Certain Non-GAAP Financial Measures in Other Items below. |
Net income for the nine months ended
Net income for the quarter ended
Consolidated revenues increased by
TOBACCO OPERATIONS
Operating income for the Tobacco Operations segment increased by
INGREDIENTS OPERATIONS
Operating income for the Ingredients Operations segment was
OTHER ITEMS
Cost of goods sold in the nine months and quarter ended
For the nine months and quarter ended
For the nine months and quarter ended
On
Reconciliation of Certain Non-GAAP Financial Measures
The following tables set forth certain non-recurring items included in reported results to reconcile adjusted operating income to consolidated operating income and adjusted net income to net income attributable to
Adjusted Operating Income Reconciliation | |||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
(in thousands) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
As Reported: Consolidated operating income | $ | 77,526 | $ | 62,773 | $ | 128,678 | $ | 103,191 | |||||||||||||||
Purchase accounting adjustment (1) | — | 3,057 | — | 3,057 | |||||||||||||||||||
Transaction costs for acquisitions(2) | — | 597 | — | 2,310 | |||||||||||||||||||
Restructuring and impairment costs(3) | — | 8,433 | — | 10,457 | |||||||||||||||||||
Fair value adjustment to contingent consideration for | — | — | — | (2,532) | |||||||||||||||||||
Adjusted operating income | $ | 77,526 | $ | 74,860 | $ | 128,678 | $ | 116,483 | |||||||||||||||
Adjusted Net Income and Diluted Earnings Per Share | |||||||||||||||||||||||
(in thousands and reported net of income taxes) | Three Months Ended | Nine Months Ended | |||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
As Reported: Net income available to | $ | 41,660 | $ | 34,940 | $ | 70,345 | $ | 60,807 | |||||||||||||||
Purchase accounting adjustment (1) | — | 2,415 | — | 2,415 | |||||||||||||||||||
Transaction costs for acquisitions(2) | — | 482 | — | 2,195 | |||||||||||||||||||
Restructuring and impairment costs(3) | — | 6,874 | — | 7,879 | |||||||||||||||||||
Fair value adjustment to contingent consideration for | — | — | — | (2,532) | |||||||||||||||||||
Interest income and income tax benefit on a final tax | — | — | — | (2,156) | |||||||||||||||||||
Interest expense reversal on uncertain tax position and | — | — | (684) | — | |||||||||||||||||||
Adjusted net income available to | $ | 41,660 | $ | 44,711 | $ | 69,661 | $ | 68,608 | |||||||||||||||
As reported: Diluted earnings per share | $ | 1.67 | $ | 1.40 | $ | 2.82 | $ | 2.44 | |||||||||||||||
As adjusted: Diluted earnings per share | $ | 1.67 | $ | 1.80 | $ | 2.80 | $ | 2.76 |
(1) | The Company recognized an increase in cost of goods sold in the third quarter of fiscal year 2022, relating to the expensing of a fair value adjustment to inventory associated with the acquisition accounting for Shank's (effective |
(2) | The Company incurred selling, general, and administrative expenses for due diligence and other transaction costs associated with the acquisition of Shank's. |
(3) | Restructuring and impairment costs are included in Consolidated operating income in the consolidated statements of income, but excluded for purposes of Adjusted operating income, Adjusted net income available to |
(4) | The Company reversed the contingent consideration liability for the |
COVID-19 PANDEMIC IMPACT
We continue to monitor global developments related to the coronavirus ("COVID-19" or "COVID") pandemic and have taken and continue to take steps intended to mitigate the potential risks and impacts to us. Mitigating risks from COVID to our employees and our business is critically important. We have assessed and regularly update our existing health and safety protocols, business continuity plans, and related policies and practices, and we continue to work with our suppliers to mitigate the impacts to our supply chain due to the pandemic. To date, we have not experienced a material impact to our supply chain, although we previously experienced delays resulting from COVID in certain operations, we experienced increased volatility in foreign currency exchange rates which we believe in part related to COVID uncertainties and actions taken by governments and central banks, and we experienced and continue to monitor for logistical constraints around worldwide vessel and container availability and increased costs stemming from the COVID pandemic. We remain thankful for the hard work of our employees and the continued support of our customers, growers, and other partners.
Additional information
Amounts described as net income (loss) and earnings (loss) per diluted share in the previous discussion are attributable to
This release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that any statements contained herein regarding financial condition, results of operation, and future business plans, operations, opportunities, and prospects for its performance are forward-looking statements based upon management's current knowledge and assumptions about future events, and involve risks and uncertainties that could cause actual results, performance, or achievements to be materially different from any anticipated results, prospects, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, impacts of the ongoing COVID-19 pandemic and new subvariants; success in pursuing strategic investments or acquisitions and integration of new businesses and the impact of these new businesses on future results; product purchased not meeting quality and quantity requirements; our reliance on a few large customers; its ability to maintain effective information technology systems and safeguard confidential information; anticipated levels of demand for and supply of its products and services; costs incurred in providing these products and services including increased transportation costs and delays attributed to global supply chain challenges; timing of shipments to customers; higher inflation rates; changes in market structure; government regulation and other stakeholder expectations; economic and political conditions in the countries in which we and our customers operate, including the ongoing impacts from the conflict in
At
CONSOLIDATED STATEMENTS OF INCOME (in thousands of dollars, except per share data) | ||||||||||||||||||||||||||
Three Months Ended December | Nine Months Ended December | |||||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
(Unaudited) | (Unaudited) | |||||||||||||||||||||||||
Sales and other operating revenues | $ | 795,039 | $ | 652,644 | $ | 1,875,845 | $ | 1,456,628 | ||||||||||||||||||
Costs and expenses | ||||||||||||||||||||||||||
Cost of goods sold | 649,539 | 521,171 | 1,540,368 | 1,169,999 | ||||||||||||||||||||||
Selling, general and administrative expenses | 67,974 | 60,267 | 206,799 | 175,513 | ||||||||||||||||||||||
Other income | — | — | — | (2,532) | ||||||||||||||||||||||
Restructuring and impairment costs | — | 8,433 | — | 10,457 | ||||||||||||||||||||||
Operating income | 77,526 | 62,773 | 128,678 | 103,191 | ||||||||||||||||||||||
Equity in pretax earnings (loss) of unconsolidated affiliates | 345 | 2,084 | 208 | 5,056 | ||||||||||||||||||||||
Other non-operating income (expense) | (69) | 56 | (208) | 158 | ||||||||||||||||||||||
Interest income | 77 | 209 | 407 | 799 | ||||||||||||||||||||||
Interest expense | 14,265 | 7,462 | 33,259 | 20,800 | ||||||||||||||||||||||
Income before income taxes and other items | 63,614 | 57,660 | 95,826 | 88,404 | ||||||||||||||||||||||
Income taxes | 12,253 | 13,505 | 22,258 | 18,582 | ||||||||||||||||||||||
Net income | 51,361 | 44,155 | 73,568 | 69,822 | ||||||||||||||||||||||
Less: net loss (income) attributable to noncontrolling interests in subsidiaries | (9,701) | (9,215) | (3,223) | (9,015) | ||||||||||||||||||||||
Net income attributable to | $ | 41,660 | $ | 34,940 | $ | 70,345 | $ | 60,807 | ||||||||||||||||||
Earnings per share: | ||||||||||||||||||||||||||
Basic | $ | 1.68 | $ | 1.41 | $ | 2.84 | $ | 2.46 | ||||||||||||||||||
Diluted | $ | 1.67 | $ | 1.40 | $ | 2.82 | $ | 2.44 |
See accompanying notes. |
CONSOLIDATED BALANCE SHEETS (in thousands of dollars) | ||||||||||||||||||||
2022 | 2021 | 2022 | ||||||||||||||||||
(Unaudited) | (Unaudited) | |||||||||||||||||||
ASSETS | ||||||||||||||||||||
Current assets | ||||||||||||||||||||
Cash and cash equivalents | $ | 71,283 | $ | 99,305 | $ | 81,648 | ||||||||||||||
Accounts receivable, net | 536,650 | 400,132 | 385,437 | |||||||||||||||||
Advances to suppliers, net | 163,237 | 126,830 | 129,838 | |||||||||||||||||
Accounts receivable—unconsolidated affiliates | 5,920 | 1,909 | 4,540 | |||||||||||||||||
Inventories—at lower of cost or net realizable value: | ||||||||||||||||||||
Tobacco | 866,380 | 855,587 | 822,513 | |||||||||||||||||
Other | 211,561 | 161,704 | 194,161 | |||||||||||||||||
Prepaid income taxes | 17,363 | 23,590 | 13,095 | |||||||||||||||||
Other current assets | 79,495 | 76,255 | 116,779 | |||||||||||||||||
Total current assets | 1,951,889 | 1,745,312 | 1,748,011 | |||||||||||||||||
Property, plant and equipment | ||||||||||||||||||||
Land | 24,142 | 24,752 | 23,959 | |||||||||||||||||
Buildings | 305,215 | 296,642 | 293,935 | |||||||||||||||||
Machinery and equipment | 679,970 | 662,504 | 668,451 | |||||||||||||||||
1,009,327 | 983,898 | 986,345 | ||||||||||||||||||
Less accumulated depreciation | (663,333) | (636,042) | (641,227) | |||||||||||||||||
345,994 | 347,856 | 345,118 | ||||||||||||||||||
Other assets | ||||||||||||||||||||
Operating lease right-of-use assets | 42,337 | 34,139 | 40,243 | |||||||||||||||||
213,881 | 214,023 | 213,998 | ||||||||||||||||||
Other intangibles, net | 82,917 | 95,790 | 92,571 | |||||||||||||||||
Investments in unconsolidated affiliates | 72,565 | 81,040 | 81,006 | |||||||||||||||||
Deferred income taxes | 10,005 | 15,676 | 11,616 | |||||||||||||||||
Pension asset | 12,740 | 13,495 | 12,667 | |||||||||||||||||
Other noncurrent assets | 32,575 | 46,197 | 41,115 | |||||||||||||||||
467,020 | 500,360 | 493,216 | ||||||||||||||||||
Total assets | $ | 2,764,903 | $ | 2,593,528 | $ | 2,586,345 |
See accompanying notes. |
CONSOLIDATED BALANCE SHEETS (in thousands of dollars) | ||||||||||||||||||||
2022 | 2021 | 2022 | ||||||||||||||||||
(Unaudited) | (Unaudited) | |||||||||||||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
Current liabilities | ||||||||||||||||||||
Notes payable and overdrafts | $ | 348,073 | $ | 252,609 | $ | 182,639 | ||||||||||||||
Accounts payable and accrued expenses | 208,187 | 221,374 | 272,042 | |||||||||||||||||
Accounts payable—unconsolidated affiliates | 57 | 8,788 | 5,308 | |||||||||||||||||
Customer advances and deposits | 5,365 | 26,341 | 13,724 | |||||||||||||||||
Accrued compensation | 21,670 | 18,803 | 27,281 | |||||||||||||||||
Income taxes payable | 3,715 | 10,742 | 7,427 | |||||||||||||||||
Current portion of operating lease liabilities | 11,160 | 9,128 | 10,303 | |||||||||||||||||
Current portion of long-term debt | — | — | — | |||||||||||||||||
Total current liabilities | 598,227 | 547,785 | 518,724 | |||||||||||||||||
Long-term debt | 616,750 | 518,547 | 518,547 | |||||||||||||||||
Pensions and other postretirement benefits | 50,773 | 52,624 | 52,890 | |||||||||||||||||
Long-term operating lease liabilities | 27,030 | 22,612 | 29,617 | |||||||||||||||||
Other long-term liabilities | 22,797 | 49,235 | 34,464 | |||||||||||||||||
Deferred income taxes | 48,584 | 43,483 | 47,334 | |||||||||||||||||
Total liabilities | 1,364,161 | 1,234,286 | 1,201,576 | |||||||||||||||||
Shareholders' equity | ||||||||||||||||||||
Preferred stock: | ||||||||||||||||||||
Series A Junior Participating Preferred Stock, no par value, 500,000 shares authorized, | — | — | — | |||||||||||||||||
Common stock, no par value, 100,000,000 shares authorized 24,555,361 shares issued and | 335,160 | 330,306 | 330,662 | |||||||||||||||||
Retained earnings | 1,102,887 | 1,090,110 | 1,094,192 | |||||||||||||||||
Accumulated other comprehensive loss | (77,255) | (104,412) | (84,311) | |||||||||||||||||
1,360,792 | 1,316,004 | 1,340,543 | ||||||||||||||||||
Noncontrolling interests in subsidiaries | 39,950 | 43,238 | 44,226 | |||||||||||||||||
Total shareholders' equity | 1,400,742 | 1,359,242 | 1,384,769 | |||||||||||||||||
Total liabilities and shareholders' equity | $ | 2,764,903 | $ | 2,593,528 | $ | 2,586,345 |
See accompanying notes. |
CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of dollars) | ||||||||||||||
Nine Months Ended | ||||||||||||||
2022 | 2021 | |||||||||||||
(Unaudited) | ||||||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||||
Net income | $ | 73,568 | $ | 69,822 | ||||||||||
Adjustments to reconcile net income to net cash used by operating activities: | ||||||||||||||
Depreciation and amortization | 42,844 | 39,110 | ||||||||||||
Net provision for losses (recoveries) on advances to suppliers | 6,127 | 2,864 | ||||||||||||
Foreign currency remeasurement (gain) loss, net | (1,335) | 6,829 | ||||||||||||
Foreign currency exchange contracts | 14,600 | 1,980 | ||||||||||||
Restructuring and impairment costs | — | 10,457 | ||||||||||||
Restructuring payments | — | (3,787) | ||||||||||||
Change in estimated fair value of contingent consideration for | — | (2,532) | ||||||||||||
Other, net | 18,632 | 1,814 | ||||||||||||
Changes in operating assets and liabilities, net | (338,286) | (178,133) | ||||||||||||
Net cash provided (used) by operating activities | (183,850) | (51,576) | ||||||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||||
Purchase of property, plant and equipment | (39,430) | (39,831) | ||||||||||||
Proceeds from sale of business, net of cash held by the business | 3,245 | — | ||||||||||||
Purchase of business, net of cash held by the business | — | (102,462) | ||||||||||||
Proceeds from sale of property, plant and equipment | 1,634 | 12,609 | ||||||||||||
Net cash used by investing activities | (34,551) | (129,684) | ||||||||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||||
Issuance of short-term debt, net | 166,109 | 151,413 | ||||||||||||
Issuance of long-term debt | 123,481 | — | ||||||||||||
Repayment of long-term debt | (23,481) | — | ||||||||||||
Dividends paid to noncontrolling interests | (6,825) | (6,733) | ||||||||||||
Repurchase of common stock | (3,448) | — | ||||||||||||
Dividends paid on common stock | (57,993) | (57,241) | ||||||||||||
Proceeds from termination of interest rate swap agreements | 11,786 | — | ||||||||||||
Debt issuance and other | (6,337) | (3,264) | ||||||||||||
Net cash provided (used) by financing activities | 203,292 | 84,175 | ||||||||||||
Effect of exchange rate changes on cash, restricted cash and cash equivalents | (1,256) | (831) | ||||||||||||
Net decrease in cash, restricted cash and cash equivalents | (16,365) | (97,916) | ||||||||||||
Cash, restricted cash and cash equivalents at beginning of year | 87,648 | 203,221 | ||||||||||||
Cash, restricted cash and cash equivalents at end of period | $ | 71,283 | $ | 105,305 | ||||||||||
Supplemental Information: | ||||||||||||||
Cash and cash equivalents | $ | 71,283 | $ | 99,305 | ||||||||||
Restricted cash (Other noncurrent assets) | — | 6,000 | ||||||||||||
Total cash, restricted cash and cash equivalents | $ | 71,283 | $ | 105,305 |
See accompanying notes. |
NOTE 1. BASIS OF PRESENTATION
NOTE 2. EARNINGS PER SHARE
The following table sets forth the computation of basic and diluted earnings per share:
Three Months Ended | Nine Months Ended December | |||||||||||||||||||||||||
(in thousands, except share and per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Basic Earnings Per Share | ||||||||||||||||||||||||||
Numerator for basic earnings per share | ||||||||||||||||||||||||||
Net income attributable to | $ | 41,660 | $ | 34,940 | $ | 70,345 | $ | 60,807 | ||||||||||||||||||
Denominator for basic earnings per share | ||||||||||||||||||||||||||
Weighted average shares outstanding | 24,770,294 | 24,792,108 | 24,772,827 | 24,761,290 | ||||||||||||||||||||||
Basic earnings per share | $ | 1.68 | $ | 1.41 | $ | 2.84 | $ | 2.46 | ||||||||||||||||||
Diluted Earnings Per Share | ||||||||||||||||||||||||||
Numerator for diluted earnings per share | ||||||||||||||||||||||||||
Net income attributable to | $ | 41,660 | $ | 34,940 | $ | 70,345 | $ | 60,807 | ||||||||||||||||||
Denominator for diluted earnings per share: | ||||||||||||||||||||||||||
Weighted average shares outstanding | 24,770,294 | 24,792,108 | 24,772,827 | 24,761,290 | ||||||||||||||||||||||
Effect of dilutive securities | ||||||||||||||||||||||||||
Employee and outside director share-based awards | 158,132 | 156,983 | 161,620 | 151,354 | ||||||||||||||||||||||
Denominator for diluted earnings per share | 24,928,426 | 24,949,091 | 24,934,447 | 24,912,644 | ||||||||||||||||||||||
Diluted earnings per share | $ | 1.67 | $ | 1.40 | $ | 2.82 | $ | 2.44 |
NOTE 3. SEGMENT INFORMATION
The Company conducts operations across two reportable operating segments, Tobacco Operations and Ingredients Operations.
The Tobacco Operations segment activities involve selecting, procuring, processing, packing, storing, shipping, and financing leaf tobacco for sale to, or for the account of, manufacturers of consumer tobacco products throughout the world. Through various operating subsidiaries located in tobacco-growing countries around the world and significant ownership interests in unconsolidated affiliates, the Company processes and/or sells flue-cured and burley tobaccos, dark air-cured tobaccos, and oriental tobaccos. Flue-cured, burley, and oriental tobaccos are used principally in the manufacture of cigarettes, and dark air-cured tobaccos are used mainly in the manufacture of cigars, pipe tobacco, and smokeless tobacco products. Some of these tobacco types are also increasingly used in the manufacture of non-combustible tobacco products that are intended to provide consumers with an alternative to traditional combustible products. The Tobacco Operations segment also provides physical and chemical product testing and smoke testing for tobacco customers. A substantial portion of the Company's Tobacco Operations' revenues are derived from sales to a limited number of large, multinational cigarette and cigar manufacturers.
The Ingredients Operations segment provides its customers with a broad variety of plant-based ingredients for both human and pet consumption. The Ingredients Operations segment utilizes a variety of value-added manufacturing processes converting raw materials into a wide spectrum of fruit and vegetable juices, concentrates, dehydrated products, flavors, and botanical extracts. Customers for the Ingredients Operations segment include large multinational food and beverage companies, smaller independent manufacturers, and retail organizations.
The Company currently evaluates the performance of its segments based on operating income after allocated overhead expenses, plus equity in the pretax earnings of unconsolidated affiliates. Operating results for the Company's reportable segments for each period presented in the consolidated statements of income and comprehensive income were as follows.
Three Months Ended December | Nine Months Ended December | |||||||||||||||||||||||||
(in thousands of dollars) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
SALES AND OTHER OPERATING REVENUES | ||||||||||||||||||||||||||
Tobacco Operations | $ | 724,589 | $ | 578,002 | $ | 1,642,682 | $ | 1,268,610 | ||||||||||||||||||
Ingredients Operations | 70,450 | 74,642 | 233,163 | 188,018 | ||||||||||||||||||||||
Consolidated sales and other operating revenues | $ | 795,039 | $ | 652,644 | $ | 1,875,845 | $ | 1,456,628 | ||||||||||||||||||
OPERATING INCOME | ||||||||||||||||||||||||||
Tobacco Operations | $ | 77,104 | $ | 69,796 | $ | 119,010 | $ | 105,599 | ||||||||||||||||||
Ingredients Operations | 767 | 3,494 | 9,876 | 10,573 | ||||||||||||||||||||||
Segment operating income | 77,871 | 73,290 | 128,886 | 116,172 | ||||||||||||||||||||||
Deduct: Equity in pretax (earnings) loss of unconsolidated affiliates (1) | (345) | (2,084) | (208) | (5,056) | ||||||||||||||||||||||
Restructuring and impairment costs (2) | — | (8,433) | — | (10,457) | ||||||||||||||||||||||
Add: Other income (loss)(3) | — | — | — | 2,532 | ||||||||||||||||||||||
Consolidated operating income | $ | 77,526 | $ | 62,773 | $ | 128,678 | $ | 103,191 |
(1) | Equity in pretax earnings (loss) of unconsolidated affiliates is included in segment operating income (Tobacco Operations), but is reported below consolidated operating income and excluded from that total in the consolidated statements of income and comprehensive income. |
(2) | Restructuring and impairment costs are excluded from segment operating income, but are included in consolidated operating income in the consolidated statements of income and comprehensive income. |
(3) | Other income represents the reversal of a portion of the contingent consideration liability associated with the acquisition of |
View original content to download multimedia:https://www.prnewswire.com/news-releases/universal-corporation-reports-nine-month-results-301742295.html
SOURCE
FAQ
What were Universal Corporation's (UVV) revenue results for the nine months ended December 31, 2022?
How did Universal Corporation's (UVV) diluted earnings per share change in Q3 2023?
What challenges did Universal Corporation's (UVV) Ingredients Operations segment face?
How did Universal Corporation (UVV) manage its financial structure recently?